original ) (raw )Dual Inhibitors of Main Protease (M Pro ) and Cathepsin L as Potent Antivirals against SARS-CoV2
Sauradip Chaudhuri
Journal of American Chemical Society, 2022
View PDFchevron_right
A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells
Daniel Maneval
ACS Chemical Biology
View PDFchevron_right
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19
Ouma Onguka
ACS Infectious Diseases, 2021
View PDFchevron_right
A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells
Jair Siqueira-neto
2020
View PDFchevron_right
Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease
Congbao Kang
Microorganisms, 2020
View PDFchevron_right
SARS-COV-2 3CL-PROTEASE Inhibitors as Antiviral Agent Against COVID-19
mohamed saadh
International Journal of Applied Pharmaceutics
View PDFchevron_right
SARS-COV-2 3CL-PROTEASE INHIBITORS AS ANTIVIRAL AGENTS AGAINST COVID-19
International Journal of Applied Pharmaceutics (IJAP)
International Journal of Applied Pharmaceutics, 2022
View PDFchevron_right
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
Pol segura
International Journal of Molecular Sciences, 2021
View PDFchevron_right
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus
Dionysia Amanatidou , Phaedra (Faidra) Eleftheriou
article, 2020
View PDFchevron_right
Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection
Stanley Perlman
Proceedings of the National Academy of Sciences, 2021
View PDFchevron_right
Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases
Samia Ali
Bioorganic & Medicinal Chemistry Letters, 2021
View PDFchevron_right
In silico Study of Pharmacological Treatments against SARS-CoV2 Main Protease
Houda Filali
Journal of Pure and Applied Microbiology, 2020
View PDFchevron_right
A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors
Lauren Blankenship
2020
View PDFchevron_right
Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro)
A. Abigail Lindsey
Journal of Medicinal Chemistry
View PDFchevron_right
Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2
Imran Hossain
Journal of Biomolecular Structure and Dynamics, 2020
View PDFchevron_right
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
Colette Quinn
Nature Communications
View PDFchevron_right
3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials
Anacleto Silva de Souza
Viruses, 2024
View PDFchevron_right
Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
Saurabh Upadhyay
International Journal of Biological Macromolecules, 2020
View PDFchevron_right
Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
Alpana Asnani
Future Journal of Pharmaceutical Sciences
View PDFchevron_right
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV2
Julian Tirado-rives
View PDFchevron_right
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
Ivan Scandale
2021
View PDFchevron_right
Potential protease inhibitors and their combinations to block SARS-CoV-2
achuthsankar s nair
Journal of Biomolecular Structure and Dynamics
View PDFchevron_right
Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
Christa Mueller
Angewandte Chemie, 2021
View PDFchevron_right
Computational Determination of Potential Inhibitors of SARS-CoV2 Main Protease
Ly Le
View PDFchevron_right
Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources
Cahyo Budiman
Microorganisms, 2021
View PDFchevron_right
A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods
amit singh
Journal of Genetic Engineering and Biotechnology, 2020
View PDFchevron_right
Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19
Yukari Itakura
View PDFchevron_right
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
Paola Storici
ACS Pharmacology & Translational Science
View PDFchevron_right